phase readout

NCT04375384: Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

RECRUITINGupdated 1mo ago

community read0 votes

Sponsor: Wake Forest University Health Sciences. Phase: PHASE2. Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma

view source ↗

Data sources

ctgov

last refreshed 1h ago

Found something off?

NCT04375384: Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Report a data issue

comments(0)